Results 101 to 110 of about 9,311 (148)

Eculizumab in treatment for complement-mediated thrombotic microangiopathy associated with acute pancreatitis. [PDF]

EXCLI J
Shettigar S, Jadvani R, Doshi D, Shah CV.   +3 more
europepmc   +1 more source

Efficacy of eculizumab discontinuation in atypical hemolytic uremic syndrome: a systematic review and meta-analysis. [PDF]

Blood Adv
Hockman A, Anuskiewicz S, Brennan E, Chowdhury SR, Coltoff A, Poston JN, Greenberg C, Djulbegovic B.   +7 more
europepmc   +1 more source

Oral Corticosteroid and Nonsteroidal Immunosuppressant Therapy Use in Patients with Myasthenia Gravis Receiving Ravulizumab, Eculizumab, or Efgartigimod in the USA. [PDF]

Neurol Ther
Saccà F, Lee J, Yee KS, Silvestri NJ, Sabatella G.   +4 more
europepmc   +1 more source

From dog bite to dialysis: complement-mediated haemolytic uraemic syndrome . [PDF]

BMJ Case Rep
Fredriksen TE, Mian BU, Dolgos S.
europepmc   +1 more source

Efficacy analysis of iptacopan in a patient with thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation: a case report. [PDF]

Front Immunol
Zhao Z, Guo L, Ge J, Wu W, Yue Y, Qiu Y, Li F, Hua W, Gu W, Lin Y.   +9 more
europepmc   +1 more source

Outcomes of Terminal Complement Blockade in Adults with High-Risk Transplant-Associated Thrombotic Microangiopathy: A Comparative Analysis. [PDF]

Transplant Cell Ther
Alhomoud M, Heller G, Cho C, Fein JA, Dahi PB, Shah GL, Politikos I, Lin R, Saldia A, Goldstein I, Jakubowski AA, Papadopoulos EB, Ponce DM, Shaffer BC, Sauter CS, Tamari R, Giralt SA, Perales MA, Scordo M.   +18 more
europepmc   +1 more source

Early recognition of atypical hemolytic uremic syndrome to prevent irreversible kidney injury: cardiac failure and refractory hypertension as critical clues in young patients. [PDF]

CEN Case Rep
Tsiamis N, Kole C, Stefanou E, Tountas C, Theodoros H, Liapis G, Kitsiou A.   +6 more
europepmc   +1 more source

Hidden in the Kidney: Renal-Limited Thrombotic Microangiopathy Without Hemolysis. [PDF]

Kidney Int Rep
Keratishvili D, Alam SF, Galeano BK, Godby RC, Alexander MP, Bentall AJ.   +5 more
europepmc   +1 more source

Complement-mediated HUS revisited: evolving insights into pathophysiology, diagnosis, and treatment. [PDF]

Front Immunol
Alyamany R, Moyer AM, Willrich MAV, Sridharan M.   +3 more
europepmc   +1 more source

Characteristics and clinical courses of patients with atypical haemolytic uraemic syndrome on dialysis withdrawal after eculizumab treatment: sub-analysis of post-marketing surveillance in Japan. [PDF]

J Nephrol
Ito S, Matsumoto M, Shimono A, Teranishi H, Maruyama S.   +4 more
europepmc   +1 more source